Esmolol

Overview

Esmolol (Brevibloc®) is an ultra-short-acting beta-adrenergic blocker used intravenously in dogs and cats for rapid control of certain tachyarrhythmias and heart rate disturbances. It is relatively cardioselective, acting primarily on beta-1 receptors within the heart.

Because of its very short duration of action, esmolol is especially useful in emergency or critical care settings where rapid onset, close titration, and quick discontinuation are desirable. Its effects typically persist for only 10 to 20 minutes after stopping an infusion.

Mechanism of Action (MOA): Esmolol blocks beta-1 adrenergic receptors in cardiac tissue, producing negative chronotropic and negative inotropic effects. This slows heart rate, reduces myocardial contractility, decreases myocardial oxygen demand, lowers blood pressure, and helps suppress adrenergically mediated supraventricular arrhythmias.

Esmolol is generally used for short-term control or assessment rather than long-term maintenance therapy, and other antiarrhythmic medications are usually required for chronic management.

Indications

Esmolol is primarily used in dogs and cats for short-term intravenous management of tachyarrhythmias and situations where rapid, reversible beta-blockade is desired. Its ultra-short duration makes it valuable in emergency, anesthesia, and intensive care settings.

• Supraventricular tachycardia (SVT): Used for acute control of rapid supraventricular rhythms.
• Atrial fibrillation: May be used to slow ventricular response rate and improve short-term rate control.
• Atrial flutter: Useful for temporary heart rate reduction in unstable or hospitalized patients.
• Atrial tachycardia: Can suppress adrenergically driven atrial tachyarrhythmias.
• Peri-anesthetic tachycardia: Used during anesthesia or procedures when excessive sympathetic stimulation causes clinically significant tachycardia.
• Diagnostic beta-blocker trial: May be used to assess tolerance or likely response before transitioning to a longer-acting beta-blocker.
• Temporary rate control in critical patients: Helpful when rapid titration and immediate discontinuation are important due to unstable cardiovascular status.

Dosage (Reference)

Dog

Esmolol is administered intravenously in dogs for rapid, short-term control of tachyarrhythmias. Because of its ultra-short duration, dosage is typically titrated to heart rate, rhythm response, blood pressure, and perfusion status.

Cat

In cats, esmolol is used intravenously for short-term rate control or arrhythmia management using the same published dosing range as dogs. Careful titration is essential because cats may be sensitive to excessive beta-blockade.

Warnings & Precautions

Esmolol is a potent intravenous beta-blocker that should be used only in patients with continuous cardiovascular monitoring and immediate access to emergency support. Because it can rapidly slow heart rate and depress myocardial function, careful titration is essential.

• Bradyarrhythmias: Contraindicated in patients with significant bradycardia, sinus node dysfunction, or clinically important slow conduction rhythms.
• AV block: Use cautiously or avoid in patients with second- or third-degree atrioventricular block unless paced or otherwise managed.
• Heart failure: Contraindicated in acute or decompensated congestive heart failure. Even patients with medically controlled heart failure may tolerate esmolol poorly.
• Hypotension: May lower blood pressure and reduce perfusion, especially in volume-depleted, anesthetized, or critically ill patients.
• Myocardial depression: Negative inotropic effects may worsen weak cardiac contractility or low-output states.
• Bronchospasm risk: Although relatively beta-1 selective, caution is advised in patients with reactive airway disease or bronchospastic disorders.
• Hypoglycemia masking: Beta-blockers may mask clinical signs of hypoglycemia such as tachycardia or tremors.
• Renal compromise: Esmolol may reduce glomerular filtration rate and potentially worsen preexisting renal impairment.
• Geriatric and cardiac patients: Adverse effects are reported more frequently in older animals with chronic heart disease or unstable cardiac status.
• Concurrent alpha-adrenergic agonists: Do not administer concurrently as stated in the supplied reference.
• IV administration only: Administer by slow bolus or controlled infusion with ECG, heart rate, blood pressure, and perfusion monitoring.
• Short duration advantage: Because effects wear off quickly after discontinuation, prompt dose reduction or stopping therapy can help manage adverse responses.

Drug Interactions

Most clinically relevant interactions with esmolol involve excessive bradycardia, hypotension, myocardial depression, altered drug concentrations, or interference with bronchodilation. Careful monitoring is required whenever esmolol is combined with other cardiovascular or anesthetic agents.

• Calcium channel blockers: Concurrent use may increase the risk of severe bradycardia, hypotension, atrioventricular block, and worsening heart failure.
• Digoxin: May potentiate bradycardia, and esmolol may increase serum digoxin concentrations.
• Anesthetics: Many anesthetic agents may enhance hypotension, myocardial depression, or slowed heart rate when used with esmolol.
• Phenothiazines (e.g., acepromazine): May increase hypotensive effects when combined.
• Antihypertensive drugs: Additive blood pressure lowering may occur.
• Diuretics: May contribute to hypotension or reduced perfusion, especially in volume-depleted patients.
• Diazepam: May enhance cardiovascular depressive or hypotensive effects according to the supplied reference.
• Morphine: May increase esmolol serum concentration and enhance clinical effects.
• Neuromuscular blocking agents / muscle relaxants: Esmolol may enhance their effects.
• Theophylline: Bronchodilatory effects may be reduced or blocked by esmolol.
• Alpha-adrenergic agonists: Concurrent administration is contraindicated in the supplied reference.

Side Effects & Overdose

Side Effects

Adverse effects of esmolol are usually related to excessive beta-blockade or reduced cardiac output. They are most commonly seen in geriatric patients, animals with chronic heart disease, or those with acute cardiac decompensation.

• Bradycardia: Excessive slowing of heart rate is one of the most common adverse effects.
• Hypotension: Blood pressure may fall due to reduced cardiac output and beta-blockade.
• AV block: Delayed atrioventricular conduction or clinically significant heart block may occur.
• Myocardial depression: Reduced contractility may worsen weak cardiac function.
• Heart failure worsening: May precipitate or aggravate congestive heart failure in susceptible patients.
• Syncope / weakness: Poor perfusion may lead to collapse, weakness, or fainting episodes.
• Bronchospasm: Respiratory distress may occur, especially in patients with airway disease.
• Hypoglycemia: May occur and can be more difficult to recognize because warning signs may be masked.
• Diarrhea: Gastrointestinal upset has been reported.
• Depression / lethargy: Reduced activity or dull mentation may occur.

Overdose

Esmolol overdose is expected to cause marked beta-blocker toxicity with cardiovascular compromise. Because the drug is ultra-short acting, signs may improve relatively quickly after discontinuation, but intensive support may still be required.

• Severe bradycardia: Marked slowing of heart rate or sinus arrest may occur.
• Profound hypotension: Weak pulses, poor perfusion, pale mucous membranes, or shock may develop.
• Advanced AV block: Serious conduction disturbances are possible.
• Acute heart failure: Pulmonary edema or worsening CHF may occur in predisposed patients.
• Collapse / altered mentation: Secondary to cerebral hypoperfusion.
• Bronchospasm: May become clinically significant in sensitive patients.
• Management: Stop infusion immediately, provide ECG and blood pressure monitoring, IV fluids as appropriate, oxygen support, and symptomatic cardiovascular treatment.
• Hospitalization: Recommended for symptomatic patients until heart rate, rhythm, blood pressure, and perfusion normalize.

Key Notes

Practical clinical points that may help optimize the safe and effective use of esmolol in dogs and cats:

• Excellent titration drug: Esmolol is especially useful when clinicians need rapid control with the option to quickly reassess and change direction.
• Bridge therapy role: Often most valuable as a temporary stabilizing medication before transitioning to a longer-acting oral beta-blocker or antiarrhythmic plan.
• Rhythm source matters: Best results occur when the underlying trigger for tachycardia (pain, hypovolemia, fever, anemia, stress, endocrine disease) is addressed simultaneously.
• Useful in anesthesia settings: Particularly practical when transient perioperative tachycardia needs control without committing to prolonged beta-blockade.
• Response can guide diagnosis: Improvement in rate after esmolol may help support a supraventricular origin for some tachyarrhythmias.
• Small dose changes matter: Incremental adjustments can significantly alter heart rate, so careful titration is more valuable than aggressive escalation.
• Perfusion over numbers: Heart rate reduction is only beneficial if tissue perfusion, mentation, pulse quality, and blood pressure remain adequate.
• ICU-friendly medication: Most beneficial in hospitals with ECG, blood pressure monitoring, and trained staff able to adjust infusions frequently.
• Not ideal for outpatient use: Because of its short action and IV requirement, esmolol is generally not a home-management drug.